| Literature DB >> 25098697 |
Su Mei Yew1, Chai Ling Chan1, Kok Wei Lee2, Shiang Ling Na1, Ruixin Tan1, Chee-Choong Hoh2, Wai-Yan Yee2, Yun Fong Ngeow1, Kee Peng Ng1.
Abstract
Dematiaceous fungi (black fungi) are a heterogeneous group of fungi present in diverse environments worldwide. Many species in this group are known to cause allergic reactions and potentially fatal diseases in humans and animals, especially in tropical and subtropical climates. This study represents the first survey of dematiaceous fungi in Malaysia and provides observations on their diversity as well as in vitro response to antifungal drugs. Seventy-five strains isolated from various clinical specimens were identified by morphology as well as an internal transcribed spacer (ITS)-based phylogenetic analysis. The combined molecular and conventional approach enabled the identification of three classes of the Ascomycota phylum and 16 genera, the most common being Cladosporium, Cochliobolus and Neoscytalidium. Several of the species identified have not been associated before with human infections. Among 8 antifungal agents tested, the azoles posaconazole (96%), voriconazole (90.7%), ketoconazole (86.7%) and itraconazole (85.3%) showed in vitro activity (MIC ≤ 1 µg/mL) to the largest number of strains, followed by anidulafungin (89.3%), caspofungin (74.7%) and amphotericin B (70.7%). Fluconazole appeared to be the least effective with only 10.7% of isolates showing in vitro susceptibility. Overall, almost half (45.3%) of the isolates showed reduced susceptibility (MIC >1 µg/mL) to at least one antifungal agent, and three strains (one Pyrenochaeta unguis-hominis and two Nigrospora oryzae) showed potential multidrug resistance.Entities:
Mesh:
Year: 2014 PMID: 25098697 PMCID: PMC4123927 DOI: 10.1371/journal.pone.0104352
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Microscopic features of dematiaceous fungi.
(A-D) Macroconidia of Curvularia, Bipolaris, Exserohilum and Alternaria (E) Arthroconidia of Neosyctalidium (F) Globose chain conidia and ramoconidia of Cladosporium (G) conidia of Daldinia (H) Dark conidia of Nigrospora (I) Chaetomium perithecium covered with long setae and dark ascospores (J) Spine-like conidiophore and hyaline conidia of Exophiala (K) Ochroconis two-celled clavate conidia with cylindrical conidiophore. Bars 20 µm.
Figure 2Classifications of fungal isolates.
Bayesian tree generated with general time reversible (GTR) model space based on unique ITS1-5.8S-ITS2 gene sequences with two strains of Saccharomyces boulardii as out-group. Isolate sequence duplicates are listed in parentheses next to their representative. Clinical isolates from UMMC used in this study are printed in bold. Bayesian posterior probability values for every clustering are printed on each node.
In vitro susceptibility of dematiaceous fungal isolates to antifungal agents, grouped according to MICa categories.
| Fungal Identity, (n | Antifungal Drugs and MIC | |||||||||||||||||||||||
| AMB | KTC | FLC | ITC | VRC | PSC | ANID | CAS | |||||||||||||||||
| A | B | C | A | B | C | A | B | C | A | B | C | A | B | C | A | B | C | A | B | C | A | B | C | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 3 | 1 | 4 | 1 | 3 | 4 | 4 | 4 | 4 | 4 | ||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 6 | 9 | 1 | 14 | 2 | 1 | 7 | 8 | 15 | 1 | 15 | 1 | 16 | 15 | 1 | 14 | 2 | |||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 8 | 8 | 2 | 5 | 1 | 8 | 7 | 1 | 8 | 8 | 8 | |||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 1 | 2 | ||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 4 | 4 | 1 | 3 | 3 | 1 | 4 | 4 | 4 | 4 | ||||||||||||||
|
| 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||||||||||
|
| 4 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 3 | 2 | 2 | 3 | 1 | 1 | 3 | |||||||
|
| 4 | 3 | 1 | 4 | 4 | 4 | 4 | 4 | 4 | |||||||||||||||
|
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | |||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||||
|
| 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||||||||||
|
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
minimum inhibitory concentration.
Number of fungal isolates.
Amphotericin B.
Ketoconazole.
Fluconazole.
Itraconazole.
Voriconazole.
Posaconazole.
Anidulafungin.
Caspofungin.
MIC categories:
Category A: ≤1 µg/mL (FLC: ≤1 µg/mL).
Category B: >1–32 µg/mL (FLC: >1–256 µg/mL).
Category C: >32 µg/mL (FLC: >256 µg/mL).
Genera and MICa profiles of potential phaeohyphomycosis aetiological agents compiled by Chowdhary et al. [43] and isolates identified in this study.
| Genus | Fungal species | Source | Case reported | MIC | ||||
| AMB | FLC | ITC | VRC | PSC | ||||
|
|
| this study |
| 12 | 4.0 | 0.5 | 0.012 | 0.75 |
|
|
| - | 0.5–8.0 | 32->64 | 0.03–0.5 | 0.5 | - | |
|
|
| - | 0.25 | - | 0.01–0.06 | 0.5 | 0.06–0.12 | |
|
|
| this study |
| 0.016 | 1.5 | 0.012 | 0.023 | 0.008 |
|
|
| - | 0.12–0.25 | >64 | 0.03–0.5 | 0.25–2.0 | 0.03–0.5 | |
|
|
| - | 0.06–0.12 | 8.0–16.0 | 0.25–0.5 | 0.05–1.0 | 0.06 | |
|
|
| - | 0.03–4.0 | 4.0->64.0 | 0.03–8.0 | 0.25–4.0 | 0.03–2.0 | |
|
| this study |
| 0.012 | 1.0 | 0.012 | 0.023 | 0.006 | |
|
|
| this study |
| <0.002–0.094 | 1.5–8 | 0.004–0.125 | 0.016–0.064 | 0.012–0.032 |
|
| this study |
| 0.003–0.064 | 0.38->256 | <0.002–0.5 | 0.008–1.0 | 0.003–0.19 | |
|
| this study |
| 0.047 | 1.5 | 0.004 | 0.016 | 0.012 | |
|
|
| - | 0.06–0.50 | 2.0–16.0 | 0.06–1.0 | 0.12–4.0 | 0.03–0.50 | |
|
|
| - | 0.12->16.0 | >64 | 0.12->16 | 0.25–1.0 | 0.03–0.5 | |
|
|
| - | 0.06->16.0 | 64->64 | 0.03->16 | 0.15->16 | 0.03–4.0 | |
|
|
| this study |
| 0.5 | 24.0 | 0.38 | 0.032 | 0.094 |
|
| this study |
| 0.047 | 2.0 | 0.064 | 0.032 | 0.018 | |
|
| this study |
| 0.064 | 6.0 | <0.002 | 0.016 | 0.016 | |
|
|
| - | 0.01–0.5 | - | 0.03–0.5 | 0.06–1.0 | 0.03–0.25 | |
|
|
| - | 0.25–4.0 | 0.12->64 | 0.01–0.12 | 0.06–1.0 | 0.01–0.06 | |
|
|
| - | 0.25–2.0 | 8.0–32.0 | 0.01–0.25 | 0.06–2.0 | 0.01–0.06 | |
|
|
| this study |
| 0.047 | 32.0 | 0.125 | 0.25 | 0.012 |
|
|
| - | 0.03–0.12 | - | 0.03–0.12 | 0.03–1.0 | 0.03–0.12 | |
| Neoscytalidium |
| this study |
| 0.008–0.064 | 0.125–16 | 0.003–12 | 0.016–0.064 | 0.003–0.125 |
|
| this study | - | 0.032 | 0.19–3 | 0.032; 1 | <0.002–0.003 | 0.008–0.047 | |
|
|
| - | 0.06–1.0 | - | 0.03->16 | 0.03–4 | 0.06–32 | |
|
|
| this study |
| >32 | 0.38->256 | 0.024–0.25 | 0.19–0.75 | 0.047–0.25 |
|
|
| - | 0.12–1.0 | 16.0->64.0 | 0.01–0.50 | 0.12–2.0 | 0.01–0.12 | |
|
|
| - | 4 | >64.0 | 0.5 | 0.12 | - | |
| Phoma |
| this study |
| 0.75 | 8.0 | 0.094 | 0.064 | 0.19 |
|
| this study |
| 0.016–0.023 | 0.19->256 | 0.19–0.25 | 0.064–0.125 | 0.125–0.19 | |
|
|
| - | 0.5-1.0 | - | 0.25–8.0 | 0.25–8.0 | - | |
| Pyrenochaeta |
| this study |
| 1.5 | >256 | >32 | >32 | >32 |
|
|
| - | 4 | >64 | 0.5 | 4 | 0.5 | |
| Rhinocladiella | R. atrovirens | this study |
| 8 | >256 | 0.19–0.38 | 0.5–0.75 | 0.008–0.047 |
|
|
| - | 1.0–2.0 | 32–64 | 0.06–0.12 | 2 | 0.06–0.12 | |
|
|
| - | 1.0->16.0 | 16.0->64.0 | 0.01–0.25 | 0.01–2.0 | 0.01–0.25 | |
The cases reported are from de Hoog et al. 2000 [19], Ellis et al. 2007 [20], Khan et al. 2009 [31], Hubka et al. 2011 [44], Mikosz et al. 2014 [45], Da Cunha et al. 2012 [46], Guarro et al. 1999 [47], Carter and Boudreaux 2004 [48], Oztas et al. 2009 [49], Rajendran et al. 2003 [50], Wang et al. 2013 [51], Aoyama et al. 2009 [52], Morio et al. 2012 [53], Hsu and Lee 1993 [54], Andes and Casadevall 2013 [55], Pappas et al. 2013 [56], Saint-jean et al. 2007 [57], Mani et al. 2008 [58], Malani et al. 2001 [59], Singh and Barde 1990 [60], English 1980 [40], Del Palacio-Hernanz et al. 1989 [61], and Rajput et al. 2011 [62].
minimum inhibitory concentration.
Amphotericin B.
Fluconazole.
Itraconazole.
Voriconazole.
Posaconazole.